Payment overview · 2025
General Payments
$179.21
9 reported records · 5 companies
Healthcare provider profile · identity verified
Jon D Harper, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT SMITH, AR · NPI 1548258361
Verified facts
What the public records show
CMS Open Payments records show Jon D Harper, MD received $179.21 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 52.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.26 | 52.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.80 | 13.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.64 | 12.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.40 | 11.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.11 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $179.21 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.26 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 627 | 157 |
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 146 |
| Simvastatin | Simvastatin | 522 | 126 |
| Lisinopril | Lisinopril | 507 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 498 | 124 |
| Losartan Potassium | Losartan Potassium | 403 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 102 |
| Potassium Chloride | Potassium Chloride | 352 | 91 |
| Omeprazole | Omeprazole | 323 | 80 |
| Gabapentin | Gabapentin | 302 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 278 | 69 |
| Meloxicam | Meloxicam | 277 | 60 |
| Furosemide | Furosemide | 270 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 68 |
| Trazodone Hcl | Trazodone Hcl | 228 | 57 |
| Metformin Hcl | Metformin Hcl | 208 | 53 |
| Eliquis | Apixaban | 184 | 36 |
| Carvedilol | Carvedilol | 179 | 46 |
| Sertraline Hcl | Sertraline Hcl | 172 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 51 |
| Alprazolam | Alprazolam | 149 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 133 | 36 |
| Warfarin Sodium | Warfarin Sodium | 123 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 31 |
| Allopurinol | Allopurinol | 111 | 28 |
| Januvia | Sitagliptin Phosphate | 110 | 18 |
| Xarelto | Rivaroxaban | 109 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 21 |
| Tramadol Hcl | Tramadol Hcl | 92 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 24 |
| Atenolol | Atenolol | 79 | 18 |
| Mirtazapine | Mirtazapine | 75 | 21 |
| Montelukast Sodium | Montelukast Sodium | 75 | 20 |
| Buspirone Hcl | Buspirone Hcl | 74 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 16 |
| Ozempic | Semaglutide | 69 | 21 |
| Clonidine Hcl | Clonidine Hcl | 66 | 12 |
| Finasteride | Finasteride | 66 | 16 |
| Metformin Hcl Er | Metformin Hcl | 65 | 13 |
| Donepezil Hcl | Donepezil Hcl | 63 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 16 |
| Prednisone | Prednisone | 62 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 54 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 20 |
| Cephalexin | Cephalexin | 53 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 13 |
| Ranolazine Er | Ranolazine | 47 | 15 |
| Sucralfate | Sucralfate | 47 | 18 |
| Nitroglycerin | Nitroglycerin | 46 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Azithromycin | Azithromycin | 26 | 20 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | 11 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Diazepam | Diazepam | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Fluconazole | Fluconazole | 20 | 12 |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amitiza | Lubiprostone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Risperidone | Risperidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179.21 · 9 records | Novo Nordisk Inc | Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error